These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30335787)

  • 1. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.
    Li Y; Hamlin DK; Chyan MK; Wong R; Dorman EF; Emery RC; Woodle DR; Manger RL; Nartea M; Kenoyer AL; Orozco JJ; Green DJ; Press OW; Storb R; Sandmaier BM; Wilbur DS
    PLoS One; 2018; 13(10):e0205135. PubMed ID: 30335787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.
    Chen Y; Kornblit B; Hamlin DK; Sale GE; Santos EB; Wilbur DS; Storer BE; Storb R; Sandmaier BM
    Blood; 2012 Feb; 119(5):1130-8. PubMed ID: 22134165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
    Wilbur DS; Thakar MS; Hamlin DK; Santos EB; Chyan MK; Nakamae H; Pagel JM; Press OW; Sandmaier BM
    Bioconjug Chem; 2009 Oct; 20(10):1983-91. PubMed ID: 19731929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a preclinical
    Crawford JR; Yang H; Kunz P; Wilbur DS; Schaffer P; Ruth TJ
    Nucl Med Biol; 2017 May; 48():31-35. PubMed ID: 28193502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
    Wilbur DS; Chyan MK; Nakamae H; Chen Y; Hamlin DK; Santos EB; Kornblit BT; Sandmaier BM
    Bioconjug Chem; 2012 Mar; 23(3):409-20. PubMed ID: 22296587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.
    Frost SH; Miller BW; Bäck TA; Santos EB; Hamlin DK; Knoblaugh SE; Frayo SL; Kenoyer AL; Storb R; Press OW; Wilbur DS; Pagel JM; Sandmaier BM
    J Nucl Med; 2015 Nov; 56(11):1766-73. PubMed ID: 26338894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
    Zalutsky MR; Zhao XG; Alston KL; Bigner D
    J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
    Nakamae H; Wilbur DS; Hamlin DK; Thakar MS; Santos EB; Fisher DR; Kenoyer AL; Pagel JM; Press OW; Storb R; Sandmaier BM
    Cancer Res; 2009 Mar; 69(6):2408-15. PubMed ID: 19244101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
    Zalutsky MR; Vaidyanathan G
    Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
    Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
    Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of [
    Naka S; Ooe K; Shirakami Y; Kurimoto K; Sakai T; Takahashi K; Toyoshima A; Wang Y; Haba H; Kato H; Tomiyama N; Watabe T
    EJNMMI Radiopharm Chem; 2024 Apr; 9(1):29. PubMed ID: 38619655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].
    Watabe T
    Gan To Kagaku Ryoho; 2022 Aug; 49(8):829-834. PubMed ID: 36046965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
    Zalutsky MR; Garg PK; Friedman HS; Bigner DD
    Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7149-53. PubMed ID: 2476813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of 211At labelled antineoplastic antibodies.
    Walte A; Sriyapureddy SS; Korkmaz Z; Krull D; Bolte O; Hofmann M; Meyer GJ; Knapp WH
    J Pharm Pharm Sci; 2007; 10(2):277s-285s. PubMed ID: 17718931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets.
    Schwarz UP; Plascjak P; Beitzel MP; Gansow OA; Eckelman WC; Waldmann TA
    Nucl Med Biol; 1998 Feb; 25(2):89-93. PubMed ID: 9468021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of cyclotron production parameters for the 209Bi(alpha, 2n) 211At reaction related to biomedical use of 211At.
    Henriksen G; Messelt S; Olsen E; Larsen RH
    Appl Radiat Isot; 2001 May; 54(5):839-44. PubMed ID: 11258534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs.
    Wang X; Ma W; Liu W; Ma H; Yang Y; Wang Y; Liu N; Yang G
    J Radiat Res; 2020 Sep; 61(5):684-690. PubMed ID: 32648573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.
    Bethge WA; Wilbur DS; Storb R; Hamlin DK; Santos EB; Brechbiel MW; Sandmaier BM
    Transplantation; 2004 Aug; 78(3):352-9. PubMed ID: 15316362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.